Greg P. Bertenshaw

BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD.

Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America.

Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL.